The European Union (EU) made the seventh of the vaccine agreements made inside the scope of combating coronavirus with Novavax.
The contract that can present 200 million doses of the potential vaccine developed by the US-based biotechnology firm Novavax in opposition to coronavirus has been authorised.
PURCHASING 200 MILLION DOSE
Within the assertion, it was famous that after the vaccine developed in keeping with the authorised contract is confirmed to be secure and efficient in opposition to coronavirus, a complete of 200 million doses can be obtained on behalf of EU member states, with 100 million doses being optionally available.
END OF SEPTEMBER TARGET: OVER 1 BILLION DOSES OF VACCINE
It was recalled that the EU had beforehand signed vaccine buy agreements with AstraZeneca, Sanofi-GSK, Johnson & Johnson, BioNTech-Pfizer, CureVac and Moderna. It was additionally said that preliminary negotiations with the Valnera firm have been accomplished.
Asserting on 27 July that it has reached its goal of vaccinating 70 p.c of the grownup inhabitants, the EU plans to procure greater than 1 billion doses of vaccine by the top of September.
VACCINATIONS ONGOING PRE-EVALUATION
The European Medicines Company (EMA) permits the use of vaccines produced by Pfizer/BioNTech, Moderna, AstraZeneca and Johnson & Johnson corporations in EU international locations to this point.
EMA continues the preliminary analysis of Sinovac, Curevac, Novavax, Sputnik V and Sanofi Pasteur vaccines.
#receive #million #doses #Novavax #vaccine
Dikkat: Sitemiz herkese açık bir platform olduğundan, çox fazla kişi paylaşım yapmaktadır. Sitenizden izinsiz paylaşım yapılması durumunda iletişim bölümünden bildirmeniz yeterlidir.